JPMorgan Chase & Co. Analysts Give Merck KGaA (FRA:MRK) a €110.00 Price Target

JPMorgan Chase & Co. set a €110.00 ($123.60) target price on Merck KGaA (FRA:MRK) in a report released on Wednesday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other equities research analysts have also recently issued research reports about the company. Warburg Research set a €106.00 ($119.10) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, May 14th. UBS Group set a €108.00 ($121.35) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, May 14th. HSBC set a €101.00 ($113.48) price target on shares of Merck KGaA and gave the company a neutral rating in a report on Monday, May 18th. Kepler Capital Markets set a €122.00 ($137.08) price target on Merck KGaA and gave the company a sell rating in a research report on Wednesday, July 1st. Finally, Deutsche Bank set a €110.00 ($123.60) target price on Merck KGaA and gave the company a neutral rating in a research note on Thursday, May 21st. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of €108.64 ($122.07).

Shares of FRA:MRK opened at €108.05 ($121.40) on Wednesday. The business has a 50-day moving average of €107.71 and a two-hundred day moving average of €106.94. Merck KGaA has a fifty-two week low of €76.60 ($86.07) and a fifty-two week high of €115.00 ($129.21).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Quiet Period Expirations

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.